The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

11 articles for AP Graves


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Substituent Effects on Drug-Receptor H-bond Interactions: Correlations Useful for the Design of Kinase Inhibitors.EBI
Glaxosmithkline
GSK114: A selective inhibitor for elucidating the biological role of TNNI3K.EBI
Glaxosmithkline
Identification of Purines and 7-Deazapurines as Potent and Selective Type I Inhibitors of Troponin I-Interacting Kinase (TNNI3K).EBI
Glaxosmithkline
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.EBI
TBA
Decoys for docking.EBI
University of California San Francisco
Discovery of Proline-Based p300/CBP Inhibitors Using DNA-Encoded Library Technology in Combination with High-Throughput Screening.EBI
Glaxosmithkline
Identification of Diarylurea Inhibitors of the Cardiac-Specific Kinase TNNI3K by Designing Selectivity Against VEGFR2, p38α, and B-Raf.EBI
Glaxosmithkline
Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor.EBI
Cellzome
Discovery of Isoxazole Amides as Potent and Selective SMYD3 Inhibitors.EBI
Glaxosmithkline
Discovery of a crystalline sulforaphane analog with good solid-state stability and engagement of the Nrf2 pathway in vitro and in vivo.EBI
Glaxosmithkline
4,6-Diaminopyrimidines as Highly Preferred Troponin I-Interacting Kinase (TNNI3K) Inhibitors.EBI
TBA